Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes
June 05, 2025 17:35 ET | Source: DENTSPLY SIRONA Inc. CHARLOTTE, N.C.,…